التفاصيل البيبلوغرافية
العنوان:
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
المؤلفون:
I’ah Donovan-Banfield , Rebekah Penrice-Randal , Hannah Goldswain , Aleksandra M. Rzeszutek , Jack Pilgrim , Katie Bullock , Geoffrey Saunders , Josh Northey , Xiaofeng Dong , Yan Ryan , Helen Reynolds , Michelle Tetlow , Lauren E. Walker , Richard FitzGerald , Colin Hale , Rebecca Lyon , Christie Woods , Shazaad Ahmad , Dennis Hadjiyiannakis , Jimstan Periselneris , Emma Knox , Calley Middleton , Lara Lavelle-Langham , Victoria Shaw , William Greenhalf , Thomas Edwards , David G. Lalloo , Christopher J. Edwards , Alistair C. Darby , Miles W. Carroll , Gareth Griffiths , Saye H. Khoo , Julian A. Hiscox , Thomas Fletcher
المصدر:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
بيانات النشر:
Nature Portfolio, 2022.
سنة النشر:
2022
المجموعة:
LCC:Science
مصطلحات موضوعية:
Science
الوصف:
Molnupiravir is an antiviral that forces lethal error catastrophe in SARS-CoV-2 RNAs. Here, the authors confirm the mechanism of action of molnupiravir in humans using samples obtained from the UK’s AGILE phase IIa clinical trial investigating the antiviral efficacy of the drug against SARS-CoV-2. No treatment-associated SARS-CoV-2 mutations were identified.
نوع الوثيقة:
article
وصف الملف:
electronic resource
اللغة:
English
تدمد:
2041-1723
العلاقة:
https://doaj.org/toc/2041-1723Test
DOI:
10.1038/s41467-022-34839-9
الوصول الحر:
https://doaj.org/article/ce55d33708154cc1b4167b313d922661Test
رقم الانضمام:
edsdoj.55d33708154cc1b4167b313d922661
قاعدة البيانات:
Directory of Open Access Journals
Full Text Finder